Medicina Legal, Psiquiatría y Patología
Departament
Eli Lilly and Company
Indianapolis, EE. UU.Publicacions en col·laboració amb investigadors/es de Eli Lilly and Company (20)
2022
-
Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients
Journal of Psychiatric Research, Vol. 145, pp. 302-308
-
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
-
Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113
2021
-
Genetic underpinnings of sociability in the general population
Neuropsychopharmacology, Vol. 46, Núm. 9, pp. 1627-1634
2019
-
A quantitative approach to neuropsychiatry: The why and the how
Neuroscience and Biobehavioral Reviews, Vol. 97, pp. 3-9
2017
-
Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: Results from the GERAS II observational study
International Psychogeriatrics, Vol. 29, Núm. 12, pp. 2081-2093
2016
2014
-
Common variant at 16p11.2 conferring risk of psychosis
Molecular Psychiatry, Vol. 19, Núm. 1, pp. 108-114
-
Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: A review of the literature
Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 16, Núm. 3
2013
-
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
Schizophrenia Research, Vol. 150, Núm. 2-3, pp. 328-333
2011
-
Efficacy of lifestyle interventions in physical health management of patients with severe mental illness
Annals of General Psychiatry, Vol. 10
2005
-
Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951
-
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting
Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486
2003
-
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481
-
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study
European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48
2001
-
Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: Results of an observational study (EFESO study)
Actas Espanolas de Psiquiatria, Vol. 29, Núm. 1, pp. 25-32
-
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)
BMC Psychiatry, Vol. 1
1997
-
Olanzapine in treatment-refractory schizophrenia: Results of an open- label study
Journal of Clinical Psychiatry, Vol. 58, Núm. 11, pp. 479-483